ダイナミック造影磁気共鳴画像法（DCE-MRI）による微粒子製剤の腫瘍移行性評価

DOI Web Site Web Site 参考文献15件

書誌事項

タイトル別名
  • Tumor Permeability of Nanocarriers Observed by Dynamic Contrast-enhanced Magnetic Resonance Imaging
  • ダイナミックゾウエイ ジキ キョウメイ ガゾウホウ DCE MRI ニ ヨル ビリュウシ セイザイ ノ シュヨウ イコウセイ ヒョウカ

この論文をさがす

抄録

  The structure of tumor vasculature is crucial for the nanocarrier-mediated chemotherapy. Recently, transforming growth factor-β (TGF-β) inhibitor was reported to increase the tumor accumulation of nanocarriers by changing the structure of tumor vasculature. To indentify the parameters of tumor vasculature function following TGF-β inhibitor (A-83-01) treatment, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was performed using Gd-DTPA and its liposomal formulation (Gd-L) as contrast agents. Observation of tumor MR image before, during, and after injection of contrast agent could calculate the parameters of vascular function, such as volume transfer constant between blood plasma and extracellular space (Ktrans) and fractional plasma volume (vp). A-83-01 treatment significantly increased these parameters within 24 h that was positively related to pericyte coverage and tumor cell proliferation. Furthermore, apparent diffusion coefficient (ADC) determined by diffusion-weighed imaging was decreased by A-83-01 treatment, suggesting the decrease of tumor interstitial fluid pressure. Vascular function of the tumor improved by A-83-01 treatment well assessed on post-Gd-L-enhanced MR images, which predicted delivery of liposomal drug to the tumor. These findings suggest that DCE-MRI and, in particular, Ktrans and vp quantitation, provide important additional information about tumor vasculature by A-83-01 treatment.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 130 (12), 1679-1685, 2010-12-01

    公益社団法人 日本薬学会

参考文献 (15)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ